RESEARCH NEWS 2016-09-30 Research News Topline data from one of three ongoing Phase 3 trials for idalopirdine indicate that patients with mild to moderate Alzheimer’s disease who took the drug declined just as fast as did those on placebo. According to a press release, drug ...
UCI MINDOrange, United States
CONFERENCE COVERAGE 2016-09-30 Conference Coverage Research into frontotemporal dementias has powered forward in the last few years, propelled by a new understanding of the underlying biology of this group of diseases. Nonetheless, one major roadblock is the lack of good animal models. ...
CONFERENCE COVERAGE 2016-09-30 Conference Coverage Researchers know the strongest genetic factors that cause frontotemporal dementia and amyotrophic lateral sclerosis: the genes for tau, progranulin, and the C9ORF72 repeat expansion. However, just as in the Alzheimer’s field, a ...
PAPER de Leeuw CA, Mooij JM, Heskes T, Posthuma D25885710
PAPER Yin L, Liu S, Li C, Ding S, Bi D, Niu Z, Han L, Li W, Gao D, Liu Z, Lu J
CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.Tumour Biol. 2016 Jul 22; PubMed: 27448305
PAPER Almeida S, Maillard C, Itin P, Hohl D, Huber M
Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.J Invest Dermatol. 2008 Mar;128(3):587-93. Epub 2007 Sep 13 PubMed: 17851586
PAPER Ferreira JV, Soares AR, Ramalho JS, Pereira P, Girao H
K63 linked ubiquitin chain formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy.Sci Rep. 2015 May 11;5:10210. PubMed: 25958982
PAPER Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, Barford D
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.Mol Cell. 2008 Feb 29;29(4):451-64. PubMed: 18313383
CONFERENCE COVERAGE 2016-09-30 Conference Coverage As frontotemporal dementia researchers gear up for trials, high up on their wish lists are better clinical outcome measures to detect change over time more sensitively than standard cognitive tests do. At the 10th International ...
PAPER Lennox RD, Wolfe RN6737217
Mass General Institute for Neurodegenerative DiseaseBoston, United States
QuanterixLexington, United States
No filters selected